These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 7889438)

  • 1. Lipoprotein(a) and apolipoproteins B and A-I after acute myocardial infarction.
    Husain M; Armstrong PW; Connelly PW; Hegele RA
    Can J Cardiol; 1995 Mar; 11(3):206-10. PubMed ID: 7889438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipoprotein(a) levels are increased in healthy young subjects with parental history of premature myocardial infarction.
    Gaeta G; Cuomo S; Capozzi G; Foglia MC; Barra S; Madrid A; Stornaiuolo V; Trevisan M
    Nutr Metab Cardiovasc Dis; 2008 Sep; 18(7):492-6. PubMed ID: 17962002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationships between lipoprotein components and risk of myocardial infarction: age, gender and short versus longer follow-up periods in the Apolipoprotein MOrtality RISk study (AMORIS).
    Holme I; Aastveit AH; Jungner I; Walldius G
    J Intern Med; 2008 Jul; 264(1):30-8. PubMed ID: 18298486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial.
    Tsimikas S; Witztum JL; Miller ER; Sasiela WJ; Szarek M; Olsson AG; Schwartz GG;
    Circulation; 2004 Sep; 110(11):1406-12. PubMed ID: 15353498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interrelationships between human apolipoprotein A-I and apolipoproteins B-48 and B-100 kinetics using stable isotopes.
    Welty FK; Lichtenstein AH; Barrett PH; Dolnikowski GG; Schaefer EJ
    Arterioscler Thromb Vasc Biol; 2004 Sep; 24(9):1703-7. PubMed ID: 15242863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of dialysis type on serum lipids, apolipoproteins, and lipoproteins.
    Kanbay M; Delibasi T; Kaya A; Aydogan T; Koca C; Akcay A; Duranay M; Yigitoglu R
    Ren Fail; 2006; 28(7):567-71. PubMed ID: 17050239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship of oxidized phospholipids and biomarkers of oxidized low-density lipoprotein with cardiovascular risk factors, inflammatory biomarkers, and effect of statin therapy in patients with acute coronary syndromes: Results from the MIRACL (Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering) trial.
    Fraley AE; Schwartz GG; Olsson AG; Kinlay S; Szarek M; Rifai N; Libby P; Ganz P; Witztum JL; Tsimikas S;
    J Am Coll Cardiol; 2009 Jun; 53(23):2186-96. PubMed ID: 19497447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship of apoE polymorphism with lipoprotein(a), apoA, apoB and lipid levels in atherosclerotic infarct.
    Tascilar N; Dursun A; Ankarali H; Mungan G; Sumbuloglu V; Ekem S; Bozdogan S; Baris S; Aciman E; Cabuk F
    J Neurol Sci; 2009 Feb; 277(1-2):17-21. PubMed ID: 18945448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of atorvastatin on Lp(a) and lipoprotein profiles in hemodialysis patients.
    Joy MS; Dornbrook-Lavender KA; Chin H; Hogan SL; Denu-Ciocca C
    Ann Pharmacother; 2008 Jan; 42(1):9-15. PubMed ID: 18000162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of fluvastatin on plasma apolipoprotein-B-containing particles, including lipoprotein(a). European Fluvastatin Study Group.
    Dallongeville J; Fruchart JC; Pfister P; Bard JM
    J Intern Med Suppl; 1994; 736():95-101. PubMed ID: 7986315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Relation of pentanucleotide repeat polymorphism of apolipoprotein (a) gene to plasma lipoprotein (a) level among Chinese patients with myocardial infarction and cerebral infarction].
    Liu X; Sun L; Li Z; Gao Y; Hui R
    Zhonghua Yi Xue Za Zhi; 2002 Oct; 82(20):1396-400. PubMed ID: 12509922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The metabolism of apolipoproteins (a) and B-100 within plasma lipoprotein (a) in human beings.
    Jenner JL; Seman LJ; Millar JS; Lamon-Fava S; Welty FK; Dolnikowski GG; Marcovina SM; Lichtenstein AH; Barrett PH; deLuca C; Schaefer EJ
    Metabolism; 2005 Mar; 54(3):361-9. PubMed ID: 15736114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Percutaneous coronary intervention results in acute increases in oxidized phospholipids and lipoprotein(a): short-term and long-term immunologic responses to oxidized low-density lipoprotein.
    Tsimikas S; Lau HK; Han KR; Shortal B; Miller ER; Segev A; Curtiss LK; Witztum JL; Strauss BH
    Circulation; 2004 Jun; 109(25):3164-70. PubMed ID: 15184281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A nine-month, placebo-controlled study of the effects of growth hormone treatment on lipoproteins and LDL size in abdominally obese men.
    Svensson J; Bengtsson BA; Taskinen MR; Wiklund O; Johannsson G
    Growth Horm IGF Res; 2000 Jun; 10(3):118-26. PubMed ID: 10942632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy--a review of the evidence.
    Walldius G; Jungner I
    J Intern Med; 2006 May; 259(5):493-519. PubMed ID: 16629855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stroke mortality and the apoB/apoA-I ratio: results of the AMORIS prospective study.
    Walldius G; Aastveit AH; Jungner I
    J Intern Med; 2006 Mar; 259(3):259-66. PubMed ID: 16476103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reference values of plasma apolipoproteins A-I and B, and association with nonlipid risk factors in the populations of two Canadian provinces: Quebec and Saskatchewan. Canadian Heart Health Surveys Research Group.
    Connelly PW; Poapst M; Davignon J; Lussier-Cacan S; Reeder B; Lessard R; Hegele RA; Csima A
    Can J Cardiol; 1999 Apr; 15(4):409-18. PubMed ID: 10322250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TRL, IDL, and LDL apolipoprotein B-100 and HDL apolipoprotein A-I kinetics as a function of age and menopausal status.
    Matthan NR; Jalbert SM; Lamon-Fava S; Dolnikowski GG; Welty FK; Barrett HR; Schaefer EJ; Lichtenstein AH
    Arterioscler Thromb Vasc Biol; 2005 Aug; 25(8):1691-6. PubMed ID: 15933247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dietary hydrogenated fat increases high-density lipoprotein apoA-I catabolism and decreases low-density lipoprotein apoB-100 catabolism in hypercholesterolemic women.
    Matthan NR; Welty FK; Barrett PH; Harausz C; Dolnikowski GG; Parks JS; Eckel RH; Schaefer EJ; Lichtenstein AH
    Arterioscler Thromb Vasc Biol; 2004 Jun; 24(6):1092-7. PubMed ID: 15087307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apolipoproteins A-I and B-markers in coronary risk evaluation.
    Agoston-Coldea L; Zdrenghea D; Pop D; Crăciun A; Rusu ML; Mocan T
    Rom J Intern Med; 2007; 45(3):251-8. PubMed ID: 18333357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.